Blood Pressure Control Following Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers: Insights from a Triple-Blind, Randomized, Clinical Trial.

What Was Tested

Researchers studied Angiotensin II in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.

Herein, the researchers present the results of replacing angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) with the calcium channel blocker (CCB) amlodipine, with or without the alpha- and beta-blocker carvedilol, to control high blood pressure in patients with coronavirus disease 2019 (COVID-19).

The continue group comprised patients who continued using their previous antihypertensive medication regimen as normal, whereas patients in the change group had their antihypertensive drugs changed to the CCB amlodipine, with or without the alpha- and beta-blocker carvedilol, based on their response to amlodipine.

Who Took Part

The abstract describes 31 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

Iranian hypertensive patients with COVID-19 and a history of taking ACEI or ARB were randomized to "continue" and "change" groups.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

PubMed files the paper under topics including Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists, Hypertension, Amlodipine, Blood Pressure, Antihypertensive Agents and Carvedilol.

The authors tagged it with the keywords acute kidney injury and calcium channel blockers.

What This Means in Plain Language

The paper is a randomized study of Angiotensin II in 31 patients in people with low blood pressure and orthostatic hypotension.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2023 (Journal of clinical pharmacology), a journal based in England.

More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.